| Literature DB >> 28171522 |
Alexandra J Lansky1,2,3, Steven R Messé4, Adam M Brickman5, Michael Dwyer6, H Bart van der Worp7, Ronald M Lazar5, Cody G Pietras1,2, Kevin J Abrams8, Eugene McFadden9, Nils H Petersen10, Jeffrey Browndyke11, Bernard Prendergast12, Vivian G Ng1,2, Donald E Cutlip13, Samir Kapadia14, Mitchell W Krucoff15, Axel Linke16, Claudia Scala Moy17, Joachim Schofer18, Gerrit-Anne van Es19, Renu Virmani20, Jeffrey Popma21, Michael K Parides21, Susheel Kodali22, Michel Bilello23, Robert Zivadinov6, Joseph Akar1, Karen L Furie24, Daryl Gress25, Szilard Voros26, Jeffrey Moses22, David Greer10, John K Forrest1, David Holmes27, Arie P Kappetein28, Michael Mack29, Andreas Baumbach3.
Abstract
Surgical and catheter-based cardiovascular procedures and adjunctive pharmacology have an inherent risk of neurological complications. The current diversity of neurological endpoint definitions and ascertainment methods in clinical trials has led to uncertainties in the neurological risk attributable to cardiovascular procedures and inconsistent evaluation of therapies intended to prevent or mitigate neurological injury. Benefit-risk assessment of such procedures should be on the basis of an evaluation of well-defined neurological outcomes that are ascertained with consistent methods and capture the full spectrum of neurovascular injury and its clinical effect. The Neurologic Academic Research Consortium is an international collaboration intended to establish consensus on the definition, classification, and assessment of neurological endpoints applicable to clinical trials of a broad range of cardiovascular interventions. Systematic application of the proposed definitions and assessments will improve our ability to evaluate the risks of cardiovascular procedures and the safety and effectiveness of preventive therapies.Entities:
Mesh：
Year: 2018 PMID： 28171522 PMCID： PMC6251670 DOI： 10.1093/eurheartj/ehx037
Source DB: PubMed Journal: Eur Heart J ISSN： 0195-668X Impact factor: 29.983